GeNeuro SA (GNRO.PA)
EUR 0.08
(6.38%)
EUR 0.08
(6.38%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -14.35 Million EUR | -9.98% |
| 2022 | -13.05 Million EUR | -73.16% |
| 2021 | -7.53 Million EUR | 6.23% |
| 2020 | -8.04 Million EUR | 18.94% |
| 2019 | -9.91 Million EUR | -122526.91% |
| 2018 | -8088.60 EUR | -40.92% |
| 2017 | -5739.90 EUR | 53.09% |
| 2016 | -12.23 Thousand EUR | -183.05% |
| 2015 | -4322.70 EUR | -100.2% |
| 2014 | 2.2 Million EUR | 165.68% |
| 2013 | -3.35 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | -7294.20 EUR | 0.0% |
| 2023 FY | -15.5 Million EUR | -18.73% |
| 2023 Q2 | -7.78 Million EUR | 0.0% |
| 2022 Q4 | -6.91 Million EUR | 0.0% |
| 2022 FY | -13.05 Million EUR | -73.16% |
| 2022 Q2 | -6.13 Million EUR | 0.0% |
| 2021 Q4 | -3.44 Million EUR | 0.0% |
| 2021 Q2 | -4.08 Million EUR | 0.0% |
| 2021 FY | -7.53 Million EUR | 6.23% |
| 2020 FY | -8.04 Million EUR | 18.94% |
| 2020 Q4 | -4.07 Million EUR | 0.0% |
| 2020 Q2 | -3.94 Million EUR | 0.0% |
| 2019 FY | -9.91 Million EUR | -122526.91% |
| 2019 Q4 | -5.09 Million EUR | 0.0% |
| 2019 Q2 | -4.82 Million EUR | 0.0% |
| 2018 Q4 | -5659.60 EUR | 0.0% |
| 2018 Q2 | -2429.00 EUR | 0.0% |
| 2018 FY | -8088.60 EUR | -40.92% |
| 2017 Q4 | 2224.10 EUR | 0.0% |
| 2017 Q2 | -7964.00 EUR | 0.0% |
| 2017 FY | -5739.90 EUR | 53.09% |
| 2016 Q4 | -6361.30 EUR | 0.0% |
| 2016 FY | -12.23 Thousand EUR | -183.05% |
| 2016 Q2 | -5874.20 EUR | 0.0% |
| 2015 Q2 | -1564.00 EUR | 0.0% |
| 2015 FY | -4322.70 EUR | -100.2% |
| 2015 Q4 | -2758.70 EUR | 0.0% |
| 2014 Q3 | 556.55 Thousand EUR | 27923.33% |
| 2014 Q1 | 556.55 Thousand EUR | 0.0% |
| 2014 Q2 | -2000.30 EUR | -100.36% |
| 2014 FY | 2.2 Million EUR | 165.68% |
| 2014 Q4 | 4201.30 EUR | -99.25% |
| 2013 FY | -3.35 Million EUR | 0.0% |
| 2013 Q1 | -851.82 Thousand EUR | 0.0% |
| 2013 Q3 | -851.82 Thousand EUR | 0.0% |
| 2013 Q4 | 556.55 Thousand EUR | 165.34% |
| 2013 Q2 | -851.82 Thousand EUR | 0.0% |
| 2012 Q4 | -851.82 Thousand EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -320.788% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 88.728% |
| Adocia SA | -17.62 Million EUR | 18.526% |
| Aelis Farma SA | -6.46 Million EUR | -122.215% |
| Biophytis S.A. | -14.33 Million EUR | -0.17% |
| Advicenne S.A. | -6.45 Million EUR | -122.352% |
| genOway Société anonyme | 2.06 Million EUR | 795.169% |
| IntegraGen SA | -183.77 Thousand EUR | -7712.646% |
| Medesis Pharma S.A. | -4.22 Million EUR | -239.469% |
| Neovacs S.A. | -6.9 Million EUR | -107.849% |
| NFL Biosciences SA | -4.43 Million EUR | -224.062% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -1744.849% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -357.639% |
| Sensorion SA | -22.31 Million EUR | 35.648% |
| Theranexus Société Anonyme | -7.64 Million EUR | -87.832% |
| TME Pharma N.V. | -5.62 Million EUR | -155.286% |
| Valbiotis SA | -7.16 Million EUR | -100.521% |
| TheraVet SA | -2.17 Million EUR | -560.073% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | 29.233% |
| argenx SE | -417.15 Million EUR | 96.558% |
| BioSenic S.A. | -7.04 Million EUR | -103.939% |
| Celyad Oncology SA | -8.45 Million EUR | -69.768% |
| DBV Technologies S.A. | -85.24 Million EUR | 83.158% |
| Galapagos NV | -88.26 Million EUR | 83.734% |
| Genfit S.A. | -26.58 Million EUR | 45.985% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | 10.228% |
| Innate Pharma S.A. | -12.66 Million EUR | -13.326% |
| Inventiva S.A. | -102.7 Million EUR | 86.021% |
| MaaT Pharma SA | -19.94 Million EUR | 28.008% |
| MedinCell S.A. | -20.97 Million EUR | 31.557% |
| Nanobiotix S.A. | -26.77 Million EUR | 46.386% |
| Onward Medical N.V. | -35.46 Million EUR | 59.515% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -215.601% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | 37.539% |
| Oxurion NV | -12.11 Million EUR | -18.557% |
| Pharming Group N.V. | -4.87 Million EUR | -194.234% |
| Poxel S.A. | -28.76 Million EUR | 50.086% |
| GenSight Biologics S.A. | -29.69 Million EUR | 51.652% |
| Transgene SA | -30.01 Million EUR | 52.161% |
| Financière de Tubize SA | -2.14 Million EUR | -569.658% |
| UCB SA | 604 Million EUR | 102.377% |
| Valneva SE | -82.08 Million EUR | 82.51% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | 50.212% |